Colonic motility in patients with type 1 diabetes and gastrointestinal symptoms.
acetylcholinesterase inhibitors
colon
diabetes mellitus
gastric emptying
gastrointestinal motility
small intestine
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
25
03
2020
revised:
22
06
2020
accepted:
25
06
2020
pubmed:
21
7
2020
medline:
9
10
2021
entrez:
21
7
2020
Statut:
ppublish
Résumé
Gastrointestinal (GI) symptoms are common in patients with diabetes mellitus (DM). The electromagnetic 3D-Transit system allows assessment of regional transit times and motility patterns throughout the GI tract. We aimed to compare GI transit times and detailed motility patterns of the colon in patients with DM and GI symptoms to those of healthy controls (HC). We further aimed to determine whether any abnormalities in motility were reversible by cholinergic stimulation. We compared 18 patients with DM with 20 HC by means of the 3D-Transit system. Patients were studied before and during oral administration of 60 mg pyridostigmine. Compared to HC, patients had prolonged gastric emptying (DM: 3.3 hours (interquartile range (IQR) 2.6-4.6); HC: 2.3 hours (IQR 1.7-2.7) (P < .01)), colonic transit time (DM: 52.6 hours (IQR 23.3-83.0); HC: 22.4 hours (IQR 18.9-43.6) (P = .02)), and whole gut transit time (DM: 69.4 hours (IQR 32.9-103.6); HC: 30.3 hours (IQR 25.2-49.9) (P < .01)). In addition, compared to HC, patients had prolonged transit time in the ascending colon (DM: 20.5 hours (IQR 11.0-44.0); HC: 8.0 hours (IQR 3.8-21.0) (P < .05)) and more slow retrograde movements in the colon (DM: 2 movements (IQR 1-4); HC: 1 movement (IQR 0-1) (P = .01)). In patients, pyridostigmine increased the number of bowel movements (P < .01) and reduced small intestine transit times (P < .05). Patients with DM and GI symptoms have longer than normal GI transit times. This is only partly reversible by pyridostigmine. The increased number of retrograde colonic movements in patients could potentially explain the abnormally long transit time in proximal colon.
Sections du résumé
BACKGROUND
Gastrointestinal (GI) symptoms are common in patients with diabetes mellitus (DM). The electromagnetic 3D-Transit system allows assessment of regional transit times and motility patterns throughout the GI tract. We aimed to compare GI transit times and detailed motility patterns of the colon in patients with DM and GI symptoms to those of healthy controls (HC). We further aimed to determine whether any abnormalities in motility were reversible by cholinergic stimulation.
METHODS
We compared 18 patients with DM with 20 HC by means of the 3D-Transit system. Patients were studied before and during oral administration of 60 mg pyridostigmine.
KEY RESULTS
Compared to HC, patients had prolonged gastric emptying (DM: 3.3 hours (interquartile range (IQR) 2.6-4.6); HC: 2.3 hours (IQR 1.7-2.7) (P < .01)), colonic transit time (DM: 52.6 hours (IQR 23.3-83.0); HC: 22.4 hours (IQR 18.9-43.6) (P = .02)), and whole gut transit time (DM: 69.4 hours (IQR 32.9-103.6); HC: 30.3 hours (IQR 25.2-49.9) (P < .01)). In addition, compared to HC, patients had prolonged transit time in the ascending colon (DM: 20.5 hours (IQR 11.0-44.0); HC: 8.0 hours (IQR 3.8-21.0) (P < .05)) and more slow retrograde movements in the colon (DM: 2 movements (IQR 1-4); HC: 1 movement (IQR 0-1) (P = .01)). In patients, pyridostigmine increased the number of bowel movements (P < .01) and reduced small intestine transit times (P < .05).
CONCLUSIONS
Patients with DM and GI symptoms have longer than normal GI transit times. This is only partly reversible by pyridostigmine. The increased number of retrograde colonic movements in patients could potentially explain the abnormally long transit time in proximal colon.
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13948Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Who WHO. Global report on Diabetes. 2016.
Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch Intern Med. 2001;161:1989-1996.
Feldman M, Schiller LR. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983;98:378-384.
Teigland T, Iversen MM, Sangnes DA, Dimcevski G, Søfteland E. A longitudinal study on patients with diabetes and symptoms of gastroparesis - associations with impaired quality of life and increased depressive and anxiety symptoms. J Diabetes Complications. 2018;32:89-94.
Talley NJ, Young L, Bytzer P, et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol. 2001;96:71-76.
Uppalapati SS, Ramzan Z, Fisher RS, Parkman HP. Factors contributing to hospitalization for gastroparesis exacerbations. Dig Dis Sci. 2009;54:2404-2409.
Gustafsson RJ, Littorin B, Berntorp K, et al. Esophageal dysmotility is more common than gastroparesis in diabetes mellitus and is associated with retinopathy. Review of Diabetic Studies. 2011;8:268-275.
Farmer AD, Pedersen AG, Brock B, et al. Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile. Diabetol. 2017;60:709-718.
Piper MS, Saad RJ. Diabetes mellitus and the colon. Current Treat Options Gastroenterol. 2017;15:460-474.
Caruana BJ, Wald A, Hinds JP, Eidelman BH. Anorectal sensory and motor function in neurogenic fecal incontinence. Comparison between multiple sclerosis and diabetes mellitus. Gastroenterology. 1991;100:465-470.
Tay SS, Wong W. Short and long-term induced effects of streptozotocin induced diabetes on the dorsal motor nucleus of the vagus nerve in the rat. Acta anatomica (Basel). 1994;150:274-281.
Guo C, Quobatari A, Shangguan Y, Hong S, Wiley JW, Quobatari A. Diabetic autonomic neuropathy: evidence for apoptosis in situ in the rat. Neurogastroenterol Motil. 2004;16:335-345.
Guy RJ, Dawson JL, Garrett JR, et al. Diabetic gastroparesis from autonomic neuropathy: Surgical considerations and changes in vagus nerve morphology. J Neurol Neurosurg Psychiatry. 1984;47:686-691.
Zhao M, Liao D, Zhao J. Diabetes-induced mechanophysiological changes in the small intestine and colon. World of diabetes. 2017;8:249-269.
Frokjaer JB, Andersen SD, Ejskjaer N, Funch-jensen P, Drewes AM, Gregersen H. Impaired contractility and remodeling of the upper gastrointestinal tract in diabetes mellitus type-1. World J Gastroenterol. 2007;13:4881-4890.
He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology. 2001;121:427-434.
Fraser RJ, Horowitz M, Maddox FA, Harding EP, Chatterton EB, Dent J. Hyperglycaemia slows gastric emptying in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 1990;33:675-680.
Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long standing type 1 diabetes. J Clin Endocrinol Metab. 2005;90:4489-4495.
Smout AJPM, Akkermans LMA. Normal and disturbed motility of the gastrointetinal tract Part 1. Anatomy and physiology. In: Normal and Disturbed Motility of the Gastrointetinal Tract. 1st ed, Routledge: Wrighton Biomedical Publishing Ldt., 1992: 11-51.
Arora Z, Mari J, Lopez R, Heinlein C, Santisi J, Birgisson S. Clinical utility of wireless motility capsule in patients with suspected multiregional gastrointestinal dysmotility. Dig Dis Sci. 2015;60:1350-1357.
Hasler WL, May KP, Wilson LA, et al. Relating gastric scintigraphy and symptoms to motility capsule transit and pressure findings in suspected gastroparesis. Neurogastroenterol Motil. 2018;30(2):1-12.
Haase A-M, Fallet S, Otto M, Scott SM, Schlageter V, Krogh K. Gastrointestinal motility during sleep assessed by tracking of telemetric capsules combined with polysomnography - a pilot study. Clin Exp Gastroenterol. 2015;8:327-332.
Fynne L, Worsoe J, Gregersen T, Schlageter V, Laurberg S, Krogh K. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol. 2011;46:1187-1193.
Worsøe J, Fynne L, Gregersen T, et al. Gastric transit and small intestinal transit time and motility assessed by a magnet tracking system. BMC Gastroenterol. 2011;11:145.
Gregersen T, Haase A-M, Schlageter V, Gronbaek H, Krogh K. Regional gastrointestinal transit times in patients with carcinoid diarrhea: assessment with the novel 3D-Transit system. J Neurogastroenterol Motility. 2015;21:423-432.
Knudsen K, Haase A-M, Fedorova TD, et al. Gastrointestinal transit time in parkinson's disease using a magnetic tracking system. J Parkinson's Disease. 2017;7:471-479.
Haase AM, Gregersen T, Christensen LA, et al. Regional gastrointestinal transit times in severe ulcerative colitis. Neurogastroenterol Motil. 2016;28:217-224.
Mark EB, Poulsen JL, Haase AM, et al. Assessment of colorectal length using the electromagnetic capsule tracking system: a comparative validation study in healthy subjects. Colorectal Dis. 2017;19(9):350-357.
Mark EB, Poulsen JL, Haase A-M, et al. Ambulatory assessment of colonic motility using the electromagnetic capsule tracking system. Neurogastroenterol Motil. 2018;31:1-11.
Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. Dis Colon Rectum. 1996;39:681-685.
Rentz AM, Kahrilas P, Stanghellini V, et al. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004;13:1737-1749.
Revicki DA, Rentz AM, Dubois D, et al. Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Qual Life Res. 2004;13:833-844.
Haase AM, Gregersen T, Schlageter V, et al. Pilot study trialling a new ambulatory method for the clinical assessment of regional gastrointestinal transit using multiple electromagnetic capsules. Neurogastroenterol Motil. 2014;26:1783-1791.
Gulichsen E, Fleisher J, Ejskjaer N, Eldrup E, Tarnow L. Screening for diabetic cardiac autonomic neuropathy using a new handheld device. J Diabetes Sci Technol. 2012;6:965-972.
NandhraGK, Mark EB, Di Tanna GL, et al. Normative values for region-specific colonic and gastrointestinal transit times in 111 healthy volunteers using the 3D-Transit electromagnet tracking system: Influence of age, gender, and body mass index. Neurogastroenterology & Motility. 2020;32 (2):e13734. http://dx.doi.org/10.1111/nmo.13734
Klinge MW, Borghammer P, Lund S, et al. Enteric cholinergic neuropathy in patients with diabetes: non-invasive assessment with positron emission tomography. Neurogastroenterol Motil. 2020;31:e13731.
Thazhath SS, Jones KL, Horowitz M, Rayner CK. Diabetic gastroparesis: Recent insights into pathophysiology and implications for management. Expert Rev Gastroenterol Hepatol. 2013;7:127-139.
Horváth VJ, Vittal H, Lörincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology. 2006;130:759-770.
Park KS, Cho KB, Hwang IS, et al. Characterization of smooth muscle, enteric nerve, interstitial cells of Cajal, and fibroblast-like cells in the gastric musculature of patients with diabetes mellitus. World J Gastroenterol. 2016;22:10131-10139.
Kim SJ, Park JH, Song DK, et al. Alterations of colonic contractility in long-term diabetic rat model. J Neurogastroenterol Motility. 2011;17:372-380.
Rouphael C, Arora Z, Thota PN, et al. Role of wireless motility capsule in the assessment and management of gastrointestinal dysmotility in patients with diabetes mellitus. Neurogastroenterol Motil. 2017;29:1-7.
Coleski R, Wilding GE, Semler JR, Hasler WL. Blunting of colon contractions in diabetics with gastroparesis quantified by wireless motility capsule methods. PLoS One. 2015;10:1-15.
Dinning PG, Zarate N, Hunt LM, et al. Pancolonic spatiotemporal mapping reveals regional deficiencies in, and disorganization of colonic propagating pressure waves in severe constipation. Neurogastroenterol Motil. 2010;22:340-349.
Bharucha AE, Low P, Camilleri M, et al. A randomised controlled study of the effect of cholinesterase inhibition on colon function in patients with diabetes mellitus and constipation. Gut. 2013;62:708-715.
Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol and Motil. 2015;27:1736-1746.
Law NM, Bharucha AE, Undale AS, Zinsmeister AR. Cholinergic stimulation enhances colonic motor activity, transit, and sensation in humans. Am J Physiol - Gastrointestinal Liver Physiol. 2001;281:1228-1237.
kloetzer L, chey WD, mccallum RW, et al. Motility of the antroduodenum in healthy and gastroparetics characterized by wireless motility capsule. Neurogastroenterol Motil. 2010;22:527-534.
Poulsen JL, Nilsson M, Brock C, Sandberg TH, Krogh K, Drewes AM. The impact of opioid treatment on regional gastrointestinal transit. J Neurogastroenterol Motility. 2016;22:282-291.